We previously showed that oncoprotein MDM2 has ubiquitin ligase activity toward tumor suppressor p53. In that paper, we showed very weak homology in the carboxyl terminal portion between MDM2 and E6AP (HECT domain). We mutated the cysteine residue (C464) corresponding to the residue essential for the ubiquitin ligase activity of E6AP and this mutation diminished the ligase activity of MDM2. The cysteine residue described above is also one of the cysteine residues that form the RING ®nger domain of MDM2. We tried to ®nd out whether the diminishing of the activity by the mutation is attributable to the disruption of the RING ®nger domain or not. When the ring ®nger domain of MDM2 was deleted, the truncation mutant did not have the ubiquitin ligase activity. When we mutated the seven cysteine residues of RING ®nger domain of MDM2 in the carboxyl terminus, the disruption of each residue in the RING ®nger completely diminished the ubiquitin ligase activity of MDM2 toward MDM2 itself and toward tumor suppressor p53. These data indicate that the RING ®nger domain in MDM2 is essential for its ubiquitin ligase activity toward p53 and itself. Oncogene (2000) 19, 1473 ± 1476.
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Keywords: MDM2; p53; ubiquitin ligase; E3; RING ®nger domain The p53 tumor suppressor gene product induces the expression of various genes (Gadd45, Waf1/p21/Cip1, cyclinG, Bax and MDM2) regulating cell-cycle arrest and apoptosis (Ko et al., 1996) . The degradation of p53 is regulated by the ubiquitin-proteasome system (Maki et al., 1996) . In the ubiquitin conjugation system, there are three enzymatic steps, i.e., E1, E2, and E3 (Ciechanover, 1998) . The E3 enzyme, ubiquitin ligase, recognizes the speci®c substrate and ubiquitinates the target protein in the presence of E1 and E2. In cells infected with human papilloma virus, HPV16 or 18, papilloma virus E6 and cellular E6AP (E6 associated protein) form complex and function as ubiquitin ligase, E3 toward p53 (Schener et al., 1993) . In non infected cells, MDM2 works as ubiquitin ligase, E3, in the presence of E1 and UbcH5 as E2 (Honda et al., 1997) . The transfection of the cells with the MDM2 gene accelerates the p53 degradation (Haupt et al., 1997; Kubbutat et al., 1997) . When the cells are exposed to genotoxic stress, the p53 is phosphorylated at ser15 through ATM kinase activation (Banin et al., 1999; Christine et al., 1999) . The phosphorylated p53 seems not to be good substrate for MDM2 (Honda et al., 1999) because of its defective binding to MDM2 (Shieh et al., 1997) . As a result, the amount of p53 in the cell increases.
There are several types of E3 or ubiquitin ligase in mammals. One of them, E6AP, works as ubiquitin ligase toward p53 in the presence of E6 protein of papilloma virus 16 or 18. The catalytic site of the ubiquitin ligase is located in the carboxyl terminal portion of E6AP and this portion is named as HECT domain. (Ciechanover, 1998) . The MDM2 may also be the HECT-type E3, because in its carboxyl terminus, there is a weak homologous sequence with HECT domain sequence ( Figure 1a ). When we aligned the sequence of the carboxyl terminal region of MDM2 with the sequence of the HECT domain of E6AP, we found that the C464 of MDM2 corresponded to the catalytic cysteine of the HECT domain (Honda et al., 1997) . When the cysteine residue (C464) in the carboxyl terminus of MDM2, which is a residue essential for the ubiquitin ligase activity of HECT protein, was mutated to alanine, the ubiquitin ligase activity was not detected any more (Honda et al., 1997) . On the other hand, this cysteine residue of MDM2 is also one of the cysteine residues in the RING domain of MDM2 (Boddy et al., 1994) . Thus, the mutation described also disrupts the RING ®nger domain. Recently, a novel component of SCF, ROC1/ Rbx1, was isolated and shown to be the catalytic site of SCF , Ohta et al., 1999 . Furthermore, the RING domain in its carboxyl terminus was shown to be essential for this catalytic activity (Ohta et al., 1999) . Also, one of the APC/C components, APC11, was shown to have similar RING ®nger domain in its carboxyl terminus , Ohta et al., 1999 .
Alignment of the sequence of the carboxyl terminus of MDM2 with the sequences of ROC1 and APC11 revealed very similar RING ®nger domains in them (Figure 1b) . When the truncated form of MDM2 (1 ± 444), in which the RING ®nger domain was deleted, was checked for the ubiquitin ligase activity, the activity toward itself (auto-ubiquitination) and that toward p53 was no longer detected (Figure 2 ). Another truncated form of MDM2 (1 ± 489), in which the RING ®nger domain was intact but the phenylalanine residue (F490) corresponding to the residue essential for the ubiquitin ligase activity of E6AP, did not lose the ubiquitin ligase activity (data not shown). This ®nding showed that the RING ®nger domain may be essential for the ubiquitin ligase activity. Then Figure 4c shows that all of the mutants could bind to p53 but they did not have ubiquitin ligase activity toward p53, although the mono, di-ubiquitinated p53 was observed in the presence of E2 (Figure 4a ). The C464 is the residue which is correspondent to the residue essential for the ubiquitin ligase of E6AP (Figure 1a) . The activity of the mutant C464A was diminished completely. Furthermore, when the cysteine residue, C449 in CXXH motif was mutated to alanine the mutant, C449A did not have ubiquitin ligase activity toward MDM2 itself nor toward p53 (Figure 4d ). These data show that the RING ®nger domain of MDM2 is essential for the ubiquitin ligase activity toward MDM2 itself and toward p53. Since the RING ®nger mutants could still bind to p53 (Figure 4c ), the function of RING ®nger domain does not seem to be substrate recognition. Since ROC1 in SCF seems to be necessary for E2 binding, the RING domain may have important role for interaction with E2.
Many proteins have been shown to have RING ®nger domains. Thus, some of these proteins may function as E3 or ubiquitin ligase at least toward themselves. Actually, recent reports suggests that RING ®nger proteins have ubiquitin ligase activity toward themselves (Lorick et al., 1999) . More recently, the RING ®nger domain of c-Cbl, an adapter protein for receptor protein-tyrosine kinases (Joazeiro et al., 1999) or Ubr1p, E3 component of the N-end rule In vitro ubiquitination assay was performed as described previously (Honda et al., 1999) . Brie¯y the standard reaction mixture (50 ml) contained Sf-9 cell extract expressing mouse E1 (500 ng), UbcH5 (500 ng), biotinylated ubiquitin (15 mg) and GST-MDM2 (500 ng) or truncated MDM2, 50 mM Tris-HCl (pH 7.4) 5 mM MgCl 2 , 2 mM ATP and 2 mM dithiothreitol (DTT). After incubation at 258C for 30 min, GST-MDM2 or truncated MDM2 was bound to glutathione Sepharose 4B resin (Pharmacia) and resolved by SDS-7.5% PAGE. The proteins in the gel were transferred to a PVDF membrane (Millipore). The PVDF membrane was incubated with ExtrAvidin (Sigma). Ubiquitinated proteins were detected by use of ECL (Amersham). When the ubiquitination of p53 was checked, p53 was added to the reaction mixture and detected by anti-p53 antibody pathway in Saccharomyces cerevisiae (Xie et al., 1999) was also shown to be required for the ubiquitin ligase activity. The ROC1/Rbx1 or APC11 possibly has catalytic ubiquitin ligase activity in SCF or APC/C but does not recognize substrate by itself. The MDM2, however, has the catalytic activity of ubiquitin ligase in the RING ®nger domain and recognizes the substrate, p53, by its amino terminal portion (Chen et al., 1993) . The amount of MDM2 proteins added to the reaction, shown in (a). (c) The binding of mutated MDM2 to p53 was checked. A Sf-9 cell extract expressing GST-MDM2 was incubated with an extract expressing p53, followed by precipitating GST-MDM2 with glutathione Sepharose 4B resin. Wildtype MDM2, mutated MDM2, and p53 bound to MDM2 were detected by immunoblotting.
(d) Ubiquitination of p53 was detected by anti-p53 antibody. Ubiquitination of MDM2 itself was detected by use of biotinylated ubiquitin as described in Figure 2 
